CD19/79b Bi-specific CAR-T Cell Therapy

Clinical trial NCT05436509 · RECRUITING

Trial details

NCT number: NCT05436509
Sponsor: Shenzhen Geno-Immune Medical Institute
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

B Cell Malignancies

Start date: 2026-06-01
Primary completion: 2029-12-31
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.